Crossmark

Raising concerns on questionable ethics approvals – a case study of 456 trials from the Institut Hospitalo-Universitaire Méditerranée Infection

Crossref DOI link: https://doi.org/10.1186/s41073-023-00134-4

Published Online: 2023-08-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Frank, Fabrice http://orcid.org/0000-0002-6524-4570
Florens, Nans http://orcid.org/0000-0002-0960-6055
Meyerowitz-katz, Gideon http://orcid.org/0000-0002-1156-9345
Barriere, Jérôme http://orcid.org/0000-0003-1113-8948
Billy, Éric http://orcid.org/0000-0002-8859-0089
Saada, Véronique http://orcid.org/0000-0001-8021-9050
Samuel, Alexander http://orcid.org/0000-0003-4547-5280
Robert, Jacques http://orcid.org/0000-0003-4380-1476
Besançon, Lonni http://orcid.org/0000-0002-7207-1276
License Information

Text and Data Mining valid from 2023-08-03

Version of Record valid from 2023-08-03
More Information

Article History

Received: 13 February 2023

Accepted: 22 May 2023

First Online: 3 August 2023

Declarations

:

: Not applicable.

: Not applicable.

: No competing interest. EB is a full-time Novartis employee. Views are his own.